However, the therapeutic benefit of TRAIL receptor (TRAIL‐R) agonists in clinical studies has been limited as cancer cells develop resistance and, in some instances, TRAIL promotes tumorigenesis (Micheau et al, 2013; von Karstedt et al, 2015). This evidence concerns the gene TNFSF10 and cancer.